DOCSLIB.ORG

HEALTHCARE CONFERENCE: CONFERENCE REVIEW Healthcare Conference:JP Morgan Healthcare Conference Conference: Review Review

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
HEALTHCARE CONFERENCE: CONFERENCE REVIEW Healthcare Conference:JP Morgan Healthcare Conference Conference: Review Review Biomedtracker Pharma intelligence | HEALTHCARE CONFERENCE: CONFERENCE REVIEW Healthcare Conference:JP Morgan Healthcare Conference Conference: Review Review Biomedtracker August 2016 / 2 Pharma intelligence | QUESTIONS? EMAIL [email protected] FOR OUR DISCLOSURES, PLEASE SEE BIOMEDTRACKER’s RESEARCH STANDARDS 1 Healthcare Conference: Conference Review JP Morgan Healthcare Conference: Review SUMMARY The 34th annual JP Morgan Healthcare Conference was held in San Francisco, CA from January 11-14, 2016. A comprehensive list of events and catalysts that were announced or updated at the conference is included in this report. Additionally, below are some key points from the conference’s company presentations. ABOUT THE AUTHORS BioMedTracker is an independent research service that offers proprietary clinical assessments and patient-based revenue forecasts of developmental drugs within a comprehensive and intuitive drug information database. Clients from the pharmaceutical, biotech, and investment industries rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication. Over the last several years, BioMedTracker has become the leader in providing objective information alongside evidence based clinical assessments and investment research on pipeline drugs worldwide. For more information on getting direct access to BioMedTracker, please email [email protected]. MedDeviceTracker is an all new medtech intelligence platform that provides clients with real-time data and analysis on medical devices and diagnostics. From the people behind BioMedTracker, comes an event-driven research service for the medical device and diagnostic marketplace. For access to MedDeviceTracker please contact your sales representative or email [email protected]. DISCLAIMER Copyright © 2016 Sagient Research This report is published by Sagient Research (the Publisher). This report contains information from reputable sources and although reasonable efforts have been made to publish accurate information, you assume sole responsibility for the selection, suitability and use of this report and acknowledge that the Publisher makes no warranties (either express or implied) as to, nor accepts liability for, the accuracy or fitness for a particular purpose of the information or advice contained herein. The Publisher wishes to make it clear that any views or opinions expressed in this report by individual authors or contributors are their personal views and opinions and do not necessarily reflect the views/opinions of the Publisher. QUESTIONS? EMAIL [email protected] FOR OUR DISCLOSURES, PLEASE SEE BIOMEDTRACKER’s RESEARCH STANDARDS 2 Biomedtracker August 2016 / 3 Pharma intelligence | Healthcare Conference: Conference Review JP Morgan Healthcare Conference: Review KEY POINTS – CONFERENCE REVIEW Medivation (MDVN) disclosed a new SREBP inhibitor, MDV4463, which has reached clinical development. The SREBP inhibitor is still being evaluated for safety but could eventually be developed for NASH, hyperlipidemia, diabetes, obesity, and metabolic syndrome. MDVN also suggested that its PD-1 inhibitor pidilizumab (which was acquired from Curetech) is likely not primarily a PD-1 inhibitor. Its MOA for efficacy is in fact not fully understood by the company, although the company is fully pursuing DLBCL as its fastest path towards regulatory approval. Finally, look forward to continued evaluation of Medivation’s lead drug, Xtandi (enzalutamide), as it expands its potential therapeutic use including data from PLATO evaluating treatment through rising PSA levels in 2H2016. Biomarin (BMRN) reported numerically positive, albeit preliminary, data from an uncontrolled Phase II trial of reveglucosidase alfa in late-onset Pompe's disease. The company needs to meet with regulators to discuss what will be needed for Phase III/registration. Ionis (IONS) presented a new analysis of data from its trial of nusinersen in infants with SMA, showing markedly improved ventilation-free survival compared to a matched natural history cohort. Officials noted the number of patients over 2 years of age with nusinersen, with a couple at least 3 years old, was unprecedented. Officials also pointed to improvements in children with SMA, with 3 non-ambulatory patients who were able to walk with treatment. Phase III trials are underway, with results expected early 2017, but officials noted they are in discussions with regulators on bringing the drug to market as quickly as possible for infants. Astellas (4503:JP) presented new data from its Japanese lung cancer study of ASP8273, its entrant into the next generation of EGFR inhibitors. ASP8273 trails Tagrisso (AZN), which has already been FDA approved, and rociletinib (CLVS), for which an NDA has already been filed. QUESTIONS? EMAIL [email protected] FOR OUR DISCLOSURES, PLEASE SEE BIOMEDTRACKER’s RESEARCH STANDARDS 3 Biomedtracker August 2016 / 4 Pharma intelligence | Healthcare Conference: Conference Review JP Morgan Healthcare Conference: Review For their cardiovascular franchise, Amgen (AMGN) reiterated important catalysts for Repatha in the second half of 2016, which should demonstrate that its LDL-c lowering does improve atherosclerosis and CV events: top-line data from both the cardiovascular outcomes study and the IVUS coronary imaging study. Officials view the latter as a complementary differentiating factor. Competitors REGN/SNY, in turn, are expecting interim analyses in Praluent's cardiovascular outcomes study in 2016, with a futility analysis at 50% of events and, in H2, a futility/overwhelming efficacy analysis at 75% of events. If those are negative, the final results are expected in H2 2017. o AMGN's presentation had Rx data showing Repatha and Praluent are currently running neck and neck, but with only about 400 total Rxs per week each. AMGN officials hope payor utilization management criteria will change with positive results from the outcomes study. o AMGN officials dismissed reports of neurotoxicity with Repatha, saying the recent source was just an anonymous post on Café Pharma. They acknowledged theoretical concerns with the novel mechanism, but pointed out factors that could mitigate cholesterol being too low, as well as the fact that Repatha does not cross the blood-brain barrier. o In heart failure, AMGN officials were excited about the prospects for omecamtiv, but still need to go through several hurdles for a decision on Phase III. Amicus (FOLD) had new, patient-level data on migalastat's impact on diarrhea in Fabry disease, showing more clearly the larger separation at higher levels of baseline symptoms, though the number of placebo patients in the higher baseline group was small. The company expects to submit answers to the day-150 EMA questions shortly, with a CHMP opinion continued to be expected early 2016. They still need to meet with the FDA later this quarter to determine on a regulatory pathway (due to mixed data). For their epidermolysis bullosa drug, Zorblisa, acquired with Scioderm, the company noted the Phase III was powered for a difference on target wound healing of ~17%. They just barely saw that degree of difference in the small Phase IIb in the ITT population (19%), but there was a substantially larger difference in the evaluable population (41%). They are also selecting patients with larger and more chronic wounds to improve the chances for a positive study. The Phase III trial is approximately half enrolled, and officials extended the estimate for top-line data to H2 2016. QUESTIONS? EMAIL [email protected] FOR OUR DISCLOSURES, PLEASE SEE BIOMEDTRACKER’s RESEARCH STANDARDS 4 Biomedtracker August 2016 / 5 Pharma intelligence | Healthcare Conference: Conference Review JP Morgan Healthcare Conference: Review Enanta (ENTA) announced nomination of FXR agonist EDP-305 as their developmental candidate for NASH (nonalcoholic steatohepatitis) and PBC (primary biliary cirrhosis). The Company is currently on track to initiate clinical trials in 2016. In preclinical data presented, EDP-305 was more potent than obeticholic acid (OCA, the active ingredient of INT-747) on FXR activation, and in the STAM mouse model, there were suggestions it may have an advantage on hepatocyte ballooning and the NAFLD activity score at a similar dose. Esperion (ESPR) reiterated the FDA has never told them they will need a CV outcomes trial completed before approval of ETC-1002—just that it must be well underway-- but said they will only be able to disclose Phase III plans in Q2 2016, after discussions with the agency (they are submitting the design of the CVOT this quarter). Their focus is on statin intolerant patients, for which no drugs have previously been formally approved. Clovis (CLVS) gave reassurance that their next-generation EGFR inhibitor, rociletinib, would both gain approval this year and be able to compete with Tagrisso (AZN), which beat it to market late last year. Officials did suggest that an ODAC is a distinct possibility, perhaps in April, but were not sure what questions the FDA would have given the rather straight-forward nature of the single-arm study. They also suggested that both Tagrisso and rociletinib would be viewed relatively comparable on efficacy in the relevant US population, and competition with thus likely come down to the different safety profiles (namely
Load more

Recommended publications
  • Print PDF Opens in a New Window
    CADTH ISSUES IN EMERGING HEALTH TECHNOLOGIES Informing Decisions About New Health Technologies Issue July 173 2018 Monoclonal Antibodies for Osteoarthritis of the Hip or Knee Image courtesy of iStock CADTH ISSUES IN EMERGING HEALTH TECHNOLOGIES 1 Authors: Sirjana Pant, Ke Xin Li, Melissa Severn Cite As: Monoclonal Antibodies for Osteoarthritis of the Hip or Knee. Ottawa: CADTH; 2018. (CADTH issues in emerging health technologies; issue 173). Acknowledgments: CADTH would like to acknowledge the contribution of Dr. Tom Appleton, MD, PhD, FRCPC, Assistant Professor, Rheumatologist; Department of Medicine, Department of Physiology and Pharmacology, The University of Western Ontario; Clinician Scientist, Lawson Health Research Institute; The Rheumatology Centre, St. Joseph’s Health Care London; for his review of the draft version of this bulletin. ISSN: 1488-6324 (online) Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy- makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.
    [Show full text]
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • DRUGS REQUIRING PRIOR AUTHORIZATION in the MEDICAL BENEFIT Page 1
    Effective Date: 08/01/2021 DRUGS REQUIRING PRIOR AUTHORIZATION IN THE MEDICAL BENEFIT Page 1 Therapeutic Category Drug Class Trade Name Generic Name HCPCS Procedure Code HCPCS Procedure Code Description Anti-infectives Antiretrovirals, HIV CABENUVA cabotegravir-rilpivirine C9077 Injection, cabotegravir and rilpivirine, 2mg/3mg Antithrombotic Agents von Willebrand Factor-Directed Antibody CABLIVI caplacizumab-yhdp C9047 Injection, caplacizumab-yhdp, 1 mg Cardiology Antilipemic EVKEEZA evinacumab-dgnb C9079 Injection, evinacumab-dgnb, 5 mg Cardiology Hemostatic Agent BERINERT c1 esterase J0597 Injection, C1 esterase inhibitor (human), Berinert, 10 units Cardiology Hemostatic Agent CINRYZE c1 esterase J0598 Injection, C1 esterase inhibitor (human), Cinryze, 10 units Cardiology Hemostatic Agent FIRAZYR icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent HAEGARDA c1 esterase J0599 Injection, C1 esterase inhibitor (human), (Haegarda), 10 units Cardiology Hemostatic Agent ICATIBANT (generic) icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent KALBITOR ecallantide J1290 Injection, ecallantide, 1 mg Cardiology Hemostatic Agent RUCONEST c1 esterase J0596 Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under Cardiology Hemostatic Agent TAKHZYRO lanadelumab-flyo J0593 direct supervision of a physician, not for use when drug is self-administered) Cardiology Pulmonary Arterial Hypertension EPOPROSTENOL (generic)
    [Show full text]
  • REGENERON PHARMACEUTICALS, INC. (Exact Name of Registrant As Specified in Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2017 (February 9, 2017) REGENERON PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) New York 000-19034 13-3444607 (State or other jurisdiction (Commission (IRS Employer of Incorporation) File No.) Identification No.) 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707 (Address of principal executive offices, including zip code) (914) 847-7000 (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Item 2.02 Results of Operations and Financial Condition. On February 9, 2017, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter and year ended December 31, 2016. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02.
    [Show full text]
  • PDCO Minutes of Meeting 18-21 May 2021
    21 May 2021 EMA/PDCO/298607/2021 Human Medicines Division Paediatric Committee (PDCO) Minutes for the meeting on 18-21 May 2021 Chair: Koenraad Norga – Vice-Chair: Sabine Scherer Virtual Meeting Disclaimers Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued). Of note, this set of minutes is a working document primarily designed for PDCO members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Shadows Cast Over JAK Class Following Xeljanz Mortality Signal
    1 March 2019 No. 3944 Scripscrip.pharmaintelligence.informa.com Pharma intelligence | informa to evaluate cardiovascular safety for both doses against an active comparator, as opposed to relying on post-marketing event reporting. On Feb. 19, Pfizer reported some results from this trial – A3921133 — and the news was alarming. Unlike prior studies, this tri- al enrolled patients who were age 50 and up and had at least one cardiovascular risk factor, the company noted. The study test- ed Xeljanz on top of background metho- trexate and included an arm with patients on a tumor necrosis factor inhibitor (TNFi). Results were monitored by an external Rheumatology Drug Safety Monitoring Board (DSMB) “Based on the most recent analysis of the ongoing A3921133 study, the DSMB observed that patients treated with to- facitinib 10 mg twice daily had a statisti- cally and clinically important difference Shadows Cast Over JAK Class in the occurrence of pulmonary em- bolism, compared with patients in this Following Xeljanz Mortality Signal study who were treated with a TNFi. The DSMB also noted an increase in overall EMILY HAYES [email protected] mortality in the 10 mg twice daily treat- ment group compared to the tofacitinib he cardiovascular risks seen with a in 2016. (Also see “PIPELINE WATCH – 10 5 mg twice daily and TNFi treatment higher-than-approved dose of Pfiz- Approvals, Two Breakthroughs And A Re- arms,” Pfizer said. T er Inc.’s Janus kinase (JAK) inhibitor fusal To File Letter” - Scrip, 1 Mar, 2016.) The This safety signal has not been picked Xeljanz in a long-term rheumatoid arthri- drug’s initial clearance came with a lot of up in adverse event reporting systems, tis study required by the US FDA have cast safety baggage.
    [Show full text]
  • July 1, 2020 RE: Physician Administered Drugs (J Codes)
    July 1, 2020 RE: Physician Administered Drugs (J Codes) Included in Prior Authorization Matrix for Molina Healthcare of New York, Inc. Dear Participating Provider: Molina Healthcare of New York, Inc. requires prior authorization for these HCPCS codes for all participating providers. Prior authorization is required before services are rendered for the codes listed. Prior authorization requests should include the most up to date patient information including office notes, consultations, labs, scans, previous treatments tried, and any other patient specific information to support the request. Please fax a completed prior authorization form along with all supporting clinical documentation to fax number: 1-844- 823-5479. Our prior authorization form and most up to date formulary can be found on our website: MolinaHealthcare.com. C9061 INJECTION, TEPROTUMUMAB-TRBW, 10 mg C9063 INJECTION, EPTINEZUMAB-JJMR, 1 mg C9122 MOMETASONE FUROATE SINUS IMPLANT, 10 micrograms (sinuva) J0122 INJECTION, ERAVACYCLINE, 1 mg J0129 Injection, abatacept 10 mg J0178 Injection, aflibercept 1 mg J0179 INJECTION, BROLUCIZUMAB-DBLL, 1MG J0185 Injection, aprepitant 1 mg J0223 INJECTION, GIVOSIRAN, 0.5 mg J0285 INJECTION, AMPHOTERICIN B, 50 mg J0490 Injection, belimumab 10 mg J0517 Injection, benralizumab 1 mg J0567 Injection, cerliponase alfa 1 mg J0584 Injection, burosumab-twza 1 mg J0585 Injection, onabotulinumtoxina, 1 unit J0587 Injection, rimabotulinumtoxinb 100 units J0599 Injection, c-1 esterase inhibitor 10 units J0641 Injection, levoleucovorin, not otherwise
    [Show full text]
  • Emerging Role of Tumor Cell Plasticity in Modifying Therapeutic Response
    Signal Transduction and Targeted Therapy www.nature.com/sigtrans REVIEW ARTICLE OPEN Emerging role of tumor cell plasticity in modifying therapeutic response Siyuan Qin1, Jingwen Jiang1,YiLu 2,3, Edouard C. Nice4, Canhua Huang1,5, Jian Zhang2,3 and Weifeng He6,7 Resistance to cancer therapy is a major barrier to cancer management. Conventional views have proposed that acquisition of resistance may result from genetic mutations. However, accumulating evidence implicates a key role of non-mutational resistance mechanisms underlying drug tolerance, the latter of which is the focus that will be discussed here. Such non-mutational processes are largely driven by tumor cell plasticity, which renders tumor cells insusceptible to the drug-targeted pathway, thereby facilitating the tumor cell survival and growth. The concept of tumor cell plasticity highlights the significance of re-activation of developmental programs that are closely correlated with epithelial–mesenchymal transition, acquisition properties of cancer stem cells, and trans- differentiation potential during drug exposure. From observations in various cancers, this concept provides an opportunity for investigating the nature of anticancer drug resistance. Over the years, our understanding of the emerging role of phenotype switching in modifying therapeutic response has considerably increased. This expanded knowledge of tumor cell plasticity contributes to developing novel therapeutic strategies or combination therapy regimens using available anticancer drugs, which are likely to
    [Show full text]
  • Valstybinės Vaistų Kontrolės Tarnybos Prie Lietuvos Respublikos Sveikatos Apsaugos Ministerijos Viršininko Į S a K Y M a S
    VALSTYBINĖS VAISTŲ KONTROLĖS TARNYBOS PRIE LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJOS VIRŠININKO Į S A K Y M A S DĖL VALSTYBINĖS VAISTŲ KONTROLĖS TARNYBOS PRIE LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTERIJOS VIRŠININKO 2006 M. LAPKRIČIO 2 D. ĮSAKYMO NR. 1A-658 „DĖL TARPTAUTINIŲ PREKĖS ŽENKLU NEREGISTRUOTŲ VAISTINIŲ MEDŽIAGŲ PAVADINIMŲ ATITIKMENŲ LIETUVIŲ KALBA SĄRAŠO PATVIRTINIMO“ PAKEITIMO 2013 m. gegužės 2 d. Nr. (1.4)1A-480 Vilnius Atsižvelgdamas į Pasaulio sveikatos organizacijos 2013 m. paskelbtą 69-ąjį Rekomenduojamų tarptautinių prekės ženklu neregistruotų vaistinių medžiagų pavadinimų (INN) sąrašą, p a k e i č i u Tarptautinių prekės ženklu neregistruotų vaistinių medžiagų pavadinimų atitikmenų lietuvių kalba sąrašą, patvirtintą Valstybinės vaistų kontrolės tarnybos prie Lietuvos Respublikos sveikatos apsaugos ministerijos viršininko 2006 m. lapkričio 2 d. įsakymu Nr. 1A-658 „Dėl Tarptautinių prekės ženklu neregistruotų vaistinių medžiagų pavadinimų atitikmenų lietuvių kalba sąrašo patvirtinimo“ (Žin., 2006, Nr. 119-4557; 2007, Nr. 13-519; 2008, Nr. 24-896; 2010, Nr. 152-7773; 2011, Nr. 56-2700, Nr. 159-7553; 2012, Nr. 53-2664, Nr. 113-5776): 1. Papildau nauja eilute, kurią po eilutės „Actodigin Aktodiginas Actodiginum“ išdėstau taip: „Actoxumab Aktoksumabas Actoxumabum“ 2. Papildau nauja eilute, kurią po eilutės „Alacizumab pegol Alacizumabas pegolas Alacizumabum pegolum“ išdėstau taip: „Aladorian Aladorianas Aladorianum“ 3. Papildau nauja eilute, kurią po eilutės „Alipogene tiparvovec Alipogenas tiparvovekas Alipogenum tiparvovecum“ išdėstau taip: „Alirocumab Alirokumabas Alirocumabum“ 4. Papildau nauja eilute, kurią po eilutės „Antithrombin alfa Antitrombinas alfa Antithrombinum alfa“ išdėstau taip: „Antithrombin gamma Antitrombinas gama Antithrombinum gamma“ 5. Papildau nauja eilute, kurią po eilutės „Astromicin Astromicinas Astromicinum“ išdėstau taip: „Asudemotide Asudemotidas Asudemotidum“ 6. Papildau nauja eilute, kurią po eilutės „Auranofin Auranofinas Auranofinum“ išdėstau taip: „Auriclosene Auriklozenas Auriclosenum“ 7.
    [Show full text]
  • Tables-Of-Phase-3-Mabs.Pdf
    Table 3. Monoclonal antibodies in Phase 2/3 or 3 clinical studies for cancer indications Most advanced Primary sponsoring company INN or code name Molecular format Target(s) phase Phase 3 indications Therapeutic area Janssen Research & Development, LLC JNJ-56022473 Humanized mAb CD123 Phase 2/3 Acute myeloid leukemia Cancer Murine IgG1, Actinium Pharmaceuticals Iomab-B radiolabeled CD45 Phase 3 Acute myeloid leukemia Cancer Humanized IgG1, Seattle Genetics Vadastuximab talirine ADC CD33 Phase 3 Acute myeloid leukemia Cancer TG Therapeutics Ublituximab Chimeric IgG1 CD20 Phase 3 Chronic lymphocytic leukemia Cancer Xencor XMAB-5574, MOR208 Humanized IgG1 CD19 Phase 2/3 Diffuse large B-cell lymphoma Cancer Moxetumomab Murine IgG1 dsFv, AstraZeneca/MedImmune LLC pasudotox immunotoxin CD22 Phase 3 Hairy cell leukemia Cancer Humanized scFv, Viventia Bio Oportuzumab monatox immunotoxin EpCAM Phase 3 Bladder cancer Cancer scFv-targeted liposome containing Merrimack Pharmaceuticals MM-302 doxorubicin HER2 Phase 2/3 Breast cancer Cancer MacroGenics Margetuximab Chimeric IgG1 HER2 Phase 3 Breast cancer Cancer Gastric cancer or gastroesophageal junction Gilead Sciences GS-5745 Humanized IgG4 MMP9 Phase 3 adenocarcinoma; ulcerative colitis (Phase 2/3) Cancer; Immune-mediated disorders Depatuxizumab Humanized IgG1, AbbVie mafodotin ADC EGFR Phase 2/3 Glioblastoma Cancer AstraZeneca/MedImmune LLC Tremelimumab Human IgG2 CTLA4 Phase 3 NSCLC, head & neck cancer, bladder cancer Cancer NSCLC, head & neck cancer, bladder cancer, breast AstraZeneca/MedImmune
    [Show full text]